Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.43 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.43 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.43 |
| ▸ | CASP7 | P55210 | 1/20 | 0.43 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.43 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.43 |
| ▸ | TERT | O14746 | 1/20 | 0.37 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.36 |
| ▸ | CASP1 | P29466 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
| ▸ | NPC1 | O15118 | 1/20 | 0.34 |
| ▸ | RAB9A | P51151 | 1/20 | 0.34 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.34 |
| ▸ | UHRF1 | Q96T88 | 1/20 | 0.33 |
| ▸ | ATAD2 | Q6PL18 | 1/20 | 0.33 |
| ▸ | S100B | P04271 | 1/20 | 0.32 |
| ▸ | CA1 | P00915 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL26512765 | 0.91 | CYP3A4 (0.46) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL404671 | 0.81 | CYP3A4 (0.35) | CYP3A4TSHRMAPK1ALDH1A1TDP1 | |
| SCHEMBL966908 | 0.79 | CYP3A4 (0.55) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL17298240 | 0.79 | CYP3A4 (0.55) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL29502024 | 0.79 | CYP3A4 (0.55) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL19884912 | 0.79 | PTK2 (0.39) | ALDH1A1CA1CA2CA3CA9 | |
| SCHEMBL3871506 | 0.79 | ACHE (0.33) | HTR2AHTR2CHTR2B | |
| SCHEMBL30391007 | 0.79 | PTK2 (0.39) | ALDH1A1CA1CA2CA3CA9 | |
| SCHEMBL832391 | 0.77 | CYP3A4 (0.60) | CYP3A4TSHRMAPK1ALDH1A1CYP1A2 | |
| SCHEMBL219912 | 0.77 | ALDH1A1 (0.40) | ALDH1A1CA1CA2CA3CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2892904-B1 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | CB THERAPEUTICS INC (KY) | 2018-10-17 | — | — | EP | disclosed |
| EP-3345907-A1 | NOVEL PYRAZOLO[3,4-d]PYRIMIDINE COMPOUND OR SALT THEREOF | Taiho Pharmaceutical Co., Ltd. (JP) | 2018-07-11 | — | — | EP | disclosed |
| US-9695175-B2 | Highly selective c-Met inhibitors as anticancer agents | CB THERAPEUTICS INC. (KY) | 2017-07-04 | — | — | US | disclosed |
| US-9695175-B2 | Highly selective c-Met inhibitors as anticancer agents | CB THERAPEUTICS INC. (KY) | 2017-07-04 | — | — | US | disclosed |
| US-9695175-B2 | Highly selective c-Met inhibitors as anticancer agents | CB THERAPEUTICS INC. (KY) | 2017-07-04 | — | — | US | disclosed |
| US-20150218171-A1 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | APOLLOMICS INC. | 2015-08-06 | — | — | US | disclosed |
| US-20150218171-A1 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | APOLLOMICS INC. | 2015-08-06 | — | — | US | disclosed |
| US-20150218171-A1 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | APOLLOMICS INC. | 2015-08-06 | — | — | US | disclosed |
| EP-2892904-A1 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | Crown Bioscience Inc. (Taiwan) (CN) | 2015-07-15 | — | — | EP | disclosed |
| WO-2014032498-A1 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | CROWN BIOSCIENCE INC. (TAICANG) (CN) | 2014-03-06 | — | — | WO | disclosed |
| WO-2014032498-A1 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | CROWN BIOSCIENCE INC. (TAICANG) (CN) | 2014-03-06 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150218171-A1 | HIGHLY SELECTIVE C-MET INHIBITORS AS ANTICANCER AGENTS | MET, MYC, HGFAC | CYP3A4 4350/4885TSHR 1944/4885MAPK1 223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.